Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies : Episode 8
Opinion
Video
PIK3CA Mutations and Delivering PI3K Inhibitors
In their discussion, the key opinion leaders explore the significance of PIK3CA mutations in HR+/HER2- metastatic breast cancer and review the findings from two pivotal clinical trials, SOLAR-1 and CAPItello-291, which investigated the efficacy of targeted therapies in patients harboring these mutations.
- Please also discuss findings from the SOLAR-1 and CAPI-tello-291 trials?
- How has the emergence of these targeted therapies impacted the treatment landscape?
- SOLAR-1 (Ciruelos et al. J. Clin Oncol. 2021)
- CAPI-tello-291 trials (NCTO4305496)
Related Videos
Related Content
